Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.

Slides:

Advertisements

Similar presentations

Dose-time-response relationship in peanut allergy using a human model of passive cutaneous anaphylaxis Anja P. Mose, MD, Charlotte G. Mortz, MD, PhD,

Advertisements

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies Marija Geroldinger-Simic, MD, Thomas Zelniker,

Allergen immunotherapy: A practice parameter third update

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE Elizabeth A. Erwin,

Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: A longitudinal analysis Rafael Pasternack, MD, PhD, Heini Huhtala, MSc, Jussi Karjalainen,

Increased peanut-specific IgA levels in saliva correlate with food challenge outcomes after peanut sublingual immunotherapy Michael Kulis, PhD, Katie.

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy Andrea Cohon, MD, L. Karla Arruda,

Is 9 more than 2 also in allergic airway inflammation?

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial Stephen.

Suzana Radulovic, MD, Mikila R. Jacobson, PhD, Stephen R

Safety of allergen immunotherapy: A 10-year prospective study

Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract Sheila M. Amar, MD, Ronald.

Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial Laila Hellkvist, MD,

Nasal allergen provocation test with multiple aeroallergens detects polysensitization in local allergic rhinitis Carmen Rondón, MD, PhD, Paloma Campo,

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

Treatment of chronic autoimmune urticaria with omalizumab

A network-based analysis of the late-phase reaction of the skin

Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind,

Phillip Lieberman, MD, Michael Tankersley, MD

Legends in allergy: Philip S. Norman and Lawrence M

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis Natalija Novak, MD,

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Selection of house dust mite–allergic patients by molecular diagnosis may enhance success of specific immunotherapy Kuan-Wei Chen, PhD, Petra Zieglmayer,

What is an “eosinophilic phenotype” of asthma?

Dose-time-response relationship in peanut allergy using a human model of passive cutaneous anaphylaxis Anja P. Mose, MD, Charlotte G. Mortz, MD, PhD,

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Cephalosporin Side Chain Cross-reactivity

Evaluation of Allergen Immunotherapy

Autophagy: Nobel Prize 2016 and allergy and asthma research

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber Thomas Werfel, MD, Annice Heratizadeh, MD, Margarete.

Advances in the approach to the patient with food allergy

High prevalence of severe asthma in a large random population study

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study Giovanni B. Pajno,

New pathways for itching in patients with atopic dermatitis?

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract Anil Nanda, MD, Maeve O'Connor, MD,

Martin Brasholt, MD, Florent Baty, PhD, Hans Bisgaard, MD, DMSci

Reply Journal of Allergy and Clinical Immunology

Thunderstorm-related asthma attacks

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis Sigurd Broesby-Olsen, MD, Thomas Kristensen,

Measles and immunomodulation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Fiftieth Annual Meeting of the American Academy of Allergy and Immunology: Anaheim, California, March 1994 Lawrence M. Lichtenstein, MD, PhD Journal.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

The GILL study: Glycerin-induced local reactions in immunotherapy

Antihistamine premedication in specific cluster immunotherapy: A double-blind, placebo- controlled study Lone Nielsen, MD, Claus R. Johnsen, MD, Holger.

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Negative affect, medication adherence, and asthma control in children

Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,

Natural history of cow’s milk allergy

Presentation transcript:

Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine Rüedi, MD, Seraina von Moos, MD, Theodor Sonderegger, PhD, Pål Johansen, PhD, Thomas M. Kündig, MD Journal of Allergy and Clinical Immunology Volume 124, Issue 5, Pages 997-1002 (November 2009) DOI: 10.1016/j.jaci.2009.07.019 Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 The patch consisted of a 3 × 5 cm polyethylene pouch that was filled with grass pollen extract in Vaseline. The side of the pouch that faced the skin was perforated. The pouch was held onto the skin by a self-adhesive tape. Journal of Allergy and Clinical Immunology 2009 124, 997-1002DOI: (10.1016/j.jaci.2009.07.019) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Participant flow. Flowchart characterizing the study population. V4, visit 4; V5, visit 5. Journal of Allergy and Clinical Immunology 2009 124, 997-1002DOI: (10.1016/j.jaci.2009.07.019) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Local eczema reactions. At visit 2, each of 6 symptoms (erythema, edema/induration/ papule formation, excoriation, weeping/exudation/scab formation, desquamation, lichenification) was recorded as none, mild, moderate, or severe, and a sum score (0-18 points) was calculated. Verum patients (open triangles) showed significantly more local reactions than placebo patients (filled triangles; Mann-Whitney exact test, P = .03). Journal of Allergy and Clinical Immunology 2009 124, 997-1002DOI: (10.1016/j.jaci.2009.07.019) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 NPTs. Scores using the allergen dose 100,000 SQ-U are depicted. The box plots show the median; the 10th, 25th, 75th, and 90th percentiles; and outliers. White box plots represent the placebo group, and gray box plots represent the allergen-treated group. Statistically significant P values are indicated where values differ from baseline (∗P < .05; ∗∗P < .01; ∗∗∗P < .001). Journal of Allergy and Clinical Immunology 2009 124, 997-1002DOI: (10.1016/j.jaci.2009.07.019) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Patient-recorded hay fever symptoms. Patients compared symptom severity during seasons 2006 and 2007 (posttreatment) with 2005 (pretreatment) and recorded scores between –10 (worst possible deterioration) and +10 (best possible improvement). Patients receiving verum (filled boxes) reported better improvement than placebo patients (open boxes; 2006, P = .02; 2007, P = .005). Box plots show median; 10th, 25th, 75th, and 90th percentiles; and outliers. Journal of Allergy and Clinical Immunology 2009 124, 997-1002DOI: (10.1016/j.jaci.2009.07.019) Copyright © 2009 American Academy of Allergy, Asthma & Immunology Terms and Conditions